Which Peptides Are Legal to Prescribe or Compound in 2026?

Which peptides are legal to prescribe or compound in 2026?

Quick answer

A peptide can be prescribed or compounded in 2026 only when the exact ingredient, form, route, prescriber, pharmacy, and compounding pathway meet the applicable rules. FDA-approved products follow their labeling, while compounded preparations must satisfy the relevant 503A or 503B requirements. Check the current FDA materials and ask the dispensing pharmacy to explain the basis for the specific preparation.

Reviewed by Taylor Anderson, RN · Aesthetic Registered Nurse · Updated September 1, 2026

Key takeaways

The exact ingredient, salt or form, route, and dosage form can change the legal answer.
503A pharmacies and 503B outsourcing facilities follow different compounding requirements.
FDA Category 1, 2, and 3 are interim evaluation categories, not a simple approved-or-banned label.
A prescription does not replace the pharmacy’s obligation to meet bulk-substance and formulation requirements.
Before paying, confirm the prescriber, dispensing pharmacy, supplier, current FDA listing, and exact preparation.
Get Hot or Die currently prescribes and dispenses medication, with care selected around your goals and budget.

A peptide’s legal status in 2026 depends on the exact ingredient, its form, the route of administration, and how the pharmacy compounds it. The same peptide name can lead to different answers when the salt, dosage form, or route changes.

Get Hot or Die currently prescribes and dispenses medication. If you want care organized around your appearance or anti-aging goals, take the Get Hot or Die personalized quiz, then ask the clinician and dispensing pharmacy to confirm the exact product details.

The four details that determine the answer

Check these details before you treat a peptide listing as a green light:

Check	Why it matters	What to confirm
Exact ingredient and form	An FDA list may name a specific substance rather than every product sold under a similar name.	Peptide name, salt or form, concentration, and dosage form.
Route of administration	FDA materials use route-specific language for some substances.	Injectable, oral, topical, or another route.
Pharmacy type	503A and 503B compounding operate under different conditions.	Patient-specific prescription, facility type, and applicable bulk-substance list.
Product type	An FDA-approved product and a compounded preparation follow different oversight systems.	Whether the clinician is prescribing an approved product or a compounded preparation.

For 503A compounding, FDA says a bulk ingredient must fit a USP or NF monograph, be a component of an FDA-approved drug when no applicable monograph exists, or appear on the applicable 503A bulk-substance list. The May 14, 2026 FDA update on 503A bulk substances explains those conditions.

How the prescription and compounding systems work

A prescription is one part of the process. The pharmacy or outsourcing facility must also operate within the rules for its type of compounding.

System	Core structure	Question to ask
503A pharmacy	Traditional, patient-specific compounding through a licensed pharmacy, generally tied to an individual prescription.	Does the ingredient and formulation meet the applicable 503A requirements?
503B outsourcing facility	FDA-registered outsourcing-facility compounding connected to the 503B bulk-substance and clinical-need framework.	Is the facility operating under the relevant 503B conditions?
FDA-approved product	A product evaluated through its own labeling and manufacturing process rather than the bulk-substance compounding lists.	Does the prescription fit the product’s labeling and the patient’s needs?

FDA maintains separate 503A and 503B bulk-substance materials. The lists change as the agency evaluates nominated substances, so a clinic menu or older article cannot settle the question by itself.

What FDA Category 1, 2, and 3 mean

FDA uses interim categories while it evaluates nominations for the 503A bulk-substance list. The categories describe FDA’s evaluation and enforcement position. They are not a universal permission slip or prohibition for every formulation.

Category	What it signals	Practical takeaway
Category 1	The substance may be eligible for the 503A list while FDA evaluates it, and FDA describes limited enforcement discretion when stated conditions are met.	Confirm the exact conditions, formulation, and route.
Category 2	FDA identified potential significant safety risks, and the substance falls outside the Category 1 enforcement-discretion policy.	A prescription or clinic listing does not settle the compounding question.
Category 3	The substance was nominated without adequate supporting information.	Treat the status as unresolved and check the latest official listing.

The FDA Category 2 page describes potential risks identified during review. FDA’s May 2026 nomination update also records category changes and explains that GHK-Cu was removed from Category 1 after its nominations were withdrawn.

Peptides that need an exact, current-status check

The examples below show why the peptide name alone is not enough. These are published 2026 details, not permanent classifications.

Peptide	Published 2026 information	What to verify
GHK-Cu	FDA’s May 14 update says “GHK-Cu (except for injectable routes of administration)” was removed from Category 1 on April 22, 2026 after nominations were withdrawn. FDA said it plans further Pharmacy Compounding Advisory Committee consultation.	Check the exact route, form, and latest FDA listing.
Ipamorelin acetate	FDA’s Category 2 page identifies potential immunogenicity concerns for certain routes, including risks related to aggregation and peptide-related impurities.	Ask the pharmacy to identify the legal basis for the specific formulation.
BPC-157	FDA materials record a withdrawn nomination and cite potential immunogenicity, peptide-impurity, and active-ingredient-characterization concerns.	Do not treat a later recommendation or marketing claim as immediate authorization to compound.
CJC-1295	A February 24, 2026 guide reported that CJC-1295 had not then been placed in Category 2. That dated report does not establish current permission.	Recheck the latest FDA materials and ask the pharmacy for its current explanation.
Thymosin Alpha-1	A secondary quick reference labels it as permitted under 503A, while other published summaries contain differing classifications.	Give the current FDA list and exact formulation more weight than a static secondary table.

When secondary peptide guides conflict, use the current FDA materials first. The CJC-1295 review from The Peptide Guides, the July 2026 update from Restorative Compounding Pharmacy + Wellness, and PeptideLaws’ compounding overview can provide context, but none replaces a current product-specific review.

Questions to ask before you pay

Write down the answers before treatment begins:

Verify	Question to ask
Product identity	What exact ingredient, form, strength, route, and dosage form will be dispensed?
Prescriber	Has a licensed clinician evaluated me and issued a patient-specific prescription where required?
Pharmacy or facility	What is the dispensing pharmacy or outsourcing facility, and which 503A or 503B rules apply?
Bulk ingredient	Who supplies the bulk substance, and how does the pharmacy verify that supplier?
Current status	Which current FDA list, category, or approved-product pathway supports this exact preparation?

FDA advises compounders to know their bulk suppliers. The agency also explains that compounded drugs are not checked through the FDA premarket approval process for safety, effectiveness, or quality before marketing. Read FDA’s compounding questions and answers for the agency’s explanation.

Choosing care around your goals

The right conversation starts with what you want to change, whether that is skin, hair, body composition, or how you feel during hormonal shifts. You can compare peptide telehealth providers for women, review what peptide therapy may cost per month, or browse the skin and glow options before speaking with a clinician.

Get Hot or Die is a current care and provider option that prescribes and dispenses medication. For any individual prescription, confirm the exact ingredient, route, dispensing details, and applicable compounding requirements with the clinician and pharmacy.

Sources

Frequently asked questions

Does a prescription automatically make a peptide legal to compound?

No. The pharmacy must still meet the applicable 503A or 503B requirements, ingredient rules, formulation conditions, and route-specific restrictions.

What does FDA Category 2 mean for a peptide?

Category 2 means FDA identified potential significant safety risks during its review. The substance falls outside FDA’s Category 1 enforcement-discretion policy.

Is GHK-Cu legal to compound in 2026?

There is no route-neutral answer. FDA’s May 2026 update describes a change involving GHK-Cu except for injectable routes, so the exact formulation and current FDA listing need review.

No. A menu does not establish that a specific preparation meets federal and state requirements. Ask for the ingredient, route, prescriber, dispensing pharmacy, and compounding basis.

How can I check a peptide’s current status before treatment?

Compare the exact ingredient and route with the latest FDA 503A or 503B materials, then ask the pharmacy to identify its compounding basis and bulk-substance supplier.

Ready to make a move?

Answer three questions to see the options, prices, and providers that fit your goals.

See My Plan

Questions women actually ask